Binding of Small-Molecule Ligands to Proteins: "What You See" Is Not Always "What You Get"

Structure

Volumn 17, Issue 4, 2009, Pages 489-498

  Mobley, David L ^a   Dill, Ken A ^b  

^a UNIVERSITY OF NEW ORLEANS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

PROTEINS

Indexed keywords

ION; LIGAND; PROTEIN; RECEPTOR; WATER;

BINDING AFFINITY; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; ENTROPY; LIGAND BINDING; MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REVIEW; SOLVATION;

BINDING SITES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; LIGANDS; MODELS, THEORETICAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; THERMODYNAMICS; WATER;

EID: 64049102289     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2009.02.010     Document Type: Review

References (148)

1. Abel R., Young T., Farid R., Berne B.J., and Friesner R.A. Role of the active-site solvent thermodynamics of factor Xa ligand binding. J. Am. Chem. Soc. 130 (2008) 2817-2831
2. Arora K., and Brooks III C.L. Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 18496-18501
3. Babaoglu K., Simeonov A., Irwin J.J., Nelson M.E., Feng B., Thomas C.J., Cancian L., Costi M.P., Maltby D.A., Jadhav A., et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem. 51 (2008) 2502-2511
4. Badger J., Minor I., Kremer M.J., Oliveira M.A., Smith T.J., Griffith J.P., Guerin D.M.A., Krishnaswamy S., Luo M., Rossmann M.G., et al. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3304-3308
5. Barillari C., Taylor J., Viner R., and Essex J.W. Classification of water molecules in protein binding sites. J. Am. Chem. Soc. 129 (2007) 2577-2587
6. Bash P.A., Singh U.C., Brown F.K., Langridge R., and Kollman P.A. Calculation of the relative change in binding free energy of a protein-inhibitor complex. Science 235 (1987) 574-576
7. Birdsall B., Feeney J., Tendler S.J.B., Hammond S.J., and Roberts G.C.K. Dihydrofolate reductase: multiple conformations and alternative modes of substrate binding. Biochemistry 28 (1989) 2297-2305
8. Boehr D.D., McElheny D., Dyson H.J., and Wright P.E. The dynamic energy landscape of dihydrofolate reductase catalysis. Science 313 (2006) 1638-1642
9. Böhm H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 8 (1993) 243-256
10. Böhm H.J., and Klebe G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs?. Angew. Chem. Int. Ed. Engl. 35 (1996) 2588-2614
11. Boresch S., Tettinger F., Leitgeb M., and Karplus M. Absolute binding free energies: a quantitative approach for their calculation. J. Phys. Chem. A 107 (2003) 9535-9551
12. Bostrom J., Hogner A., and Schmitt S. Do structurally similar ligands bind in a similar fashion?. J. Med. Chem. 49 (2006) 6716-6725
13. Brenk R., Vetter S.W., Boyce S.E., Goodin D.B., and Shoichet B.K. Probing molecular docking at a charged model binding site. J. Mol. Biol. 357 (2006) 1449-1470
14. Chang C.E., and Gilson M.K. Free energy, entropy, and induced fit in host-guest recognition: calculations with the second-generation mining minima algorithm. J. Am. Chem. Soc. 126 (2004) 13156-13164
15. Chang C.E., Chen W., and Gilson M.K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 1534-1539
16. Charifson P.S., and Kuntz I.D. Recent successes and continuing limitations in computer aided drug design. In: Charifson P.S. (Ed). Practical Application of Computer Aided Drug Design (1997), Dekker, New York
17. Cheatham T.E., Srinivasan J., Case D.A., and Kollman P.A. Molecular dynamics and continuum solvent studies of the stability of polyG-polyC and polyA-polyT DNA duplexes in solution. J. Biomol. Struct. Dyn. 16 (1998) 265-280
18. Chen W., Chang C.E., and Gilson M.K. Calculation of cyclodextrin binding affinities: energy, entropy, and implications for drug design. Biophys. J. 87 (2004) 3035-3049
19. Chen Y., Minasov G., Roth T.A., Prati F., and Shoichet B.K. The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J. Am. Chem. Soc. 128 (2006) 2970-2976
20. Chou J.J., and Bax A. Protein side-chain rotamers from dipolar couplings in a liquid crystalline phase. J. Am. Chem. Soc. 123 (2001) 3844-3845
21. Constantine K.L., Mueller L., Metzler W.J., McDonnell P.A., Todderud G., Goldfarb V., Fan Y., Newitt J.A., Keifer S.E., Gao M., et al. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects. J. Med. Chem. 51 (2008) 6225-6229
22. Corbeil C.R., Englebienne P., and Moitessier N. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J. Chem. Inf. Model. 47 (2007) 435-449
23. Cozzini P., Kellogg G.E., Spyrakis F., Abraham D.J., Constntino G., Emerson A., Fanelli F., Gohlke H., Kuhn L.A., Morris G.M., et al. Target flexibility: an emerging consideration in drug discovery and design. J. Med. Chem. 51 (2008) 6237-6255
24. Czodrowski P., Sotriffer C.A., and Klebe G. Atypical protonation states in the active site of HIV-1 protease: a computational study. J. Chem. Inf. Model. 47 (2007) 1590-1598
25. Deng Y., and Roux B. Calculation of standard binding free energies: aromatic molecules in the T4 lysozyme L99A mutant. J. Chem. Theory Comput. 2 (2006) 1255-1273
26. Deng H., Zhadin N., and Callender R. Dynamics of protein ligand binding on multiple time scales: NADH binding to lactate dehydrogenase. Biochemistry 40 (2001) 3767-3773
27. Dullweber F., Stubbs M.T., Musil D., Sturzebecher J., and Klebe G. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 313 (2001) 593-614
28. Eisenmesser E.Z., Bosco D.A., Akke M., and Kern D. Enzyme dynamics during catalysis. Science 295 (2002) 1520-1523
29. Eisenmesser E.Z., Millet O., Labeikovsky W., Korzhnev D.M., Wolf-Watz M., Bosco D.A., Skalicky J.J., Kay L.E., and Kern D. Intrinsic dynamics of an enzyme underlies catalysis. Nature 438 (2005) 117-121
30. Ferrara P., Gohlke H., Price D.J., Klebe G., Charles L., and Brooks I.I.I. Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 47 (2004) 3032-3047
31. Fragai M., Luchinat C., and Parigi G. "Four-dimensional" protein structures: examples from metalloproteins. Acc. Chem. Res. 39 (2006) 909-917
32. Fujitani H., Tanida Y., Ito M., Shirts M.R., Jayachandran G., Snow C.D., Sorin E.J., and Pande V.S. Direct calculation of the binding free energies of FKBP ligands. J. Chem. Phys. 123 (2005) 084108
33. Furet P., Meyer T., Strauss A., Raccuglia S., and Rondeau J.M. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12 (2002) 221-224
34. Gatti D.L., Palfrey B.A., Lah M.S., Entsch B., Massey V., Ballou D.P., and Ludwig M.L. The mobile flavin of 4-OH benzoate hydroxylase. Science 266 (1994) 110-114
35. Gerstein M., Lesk A.M., and Chothia C. Structural mechanisms for domain movements in proteins. Biochemistry 33 (1994) 6739-6749
36. Gilson M.K., and Zhou H.-X. Calculation of protein-ligand binding affinities. Annu. Rev. Biophys. Biomol. Struct. 36 (2007) 21-42
37. Gohlke H., and Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. 41 (2002) 2645-2676
38. Graves A.P., Brenk R., and Shoichet B.K. Decoys for docking. J. Med. Chem. 48 (2005) 3714-3728
39. Graves A.P., Shivakumar D.M., Boyce S.E., Jacobson M.P., Case D.A., and Shoichet B.K. Rescoring docking hit lists for model cavity sites: predictions and experimental testing. J. Mol. Biol. 377 (2008) 914-934
40. Greer J., Erickson J.W., Baldwin J.J., and Varney M.D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 37 (1994) 1035-1047
41. Guimaraes C.R.W., and Cardozo M. MM-GB/SA rescoring of docking poses in structure-based lead optimization. J. Chem. Inf. Model. 48 (2008) 958-970
42. Gutteridge A., and Thornton J. Conformational changes observed in enzyme crystal structures upon substrate binding. J. Mol. Biol. 346 (2005) 21-28
43. Hamelberg D., and McCammon J.A. Standard free energy of releasing a localized water molecule from the binding pockets of proteins: double-decoupling method. J. Am. Chem. Soc. 126 (2004) 7683-7689
44. Hao M.H., Haq O., and Muegge I. Torsion angle preference and energetics of small-molecule ligands bound to proteins. J. Chem. Inf. Model. 47 (2007) 2242-2252
45. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., Fisher T.E., Embrey M., Guare Jr. J.P., Egbertson M.S., et al. A napthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11233-11238
46. Head M.S., Given J.A., and Gilson M.K. "Mining minima": direct computation of conformational free energy. J. Phys. Chem. A 101 (1997) 1609-1618
47. Helms V., and Wade R.C. Thermodynamics of water mediating protein-ligand interactions in cytochrome P450cam: a molecular dynamics study. Biophys. J. 69 (1995) 810-824
48. Helms V., and Wade R.C. Computational alchemy to calculate absolute protein-ligand binding free energy. J. Am. Chem. Soc. 120 (1998) 2710-2713
49. Helms V., and Wade R.C. Hydration energy landscape of the active site cavity in cytochrome P450cam. Proteins Struct. Funct. Genet. 32 (1998) 381-396
50. Henzler-Wildman K., and Kern D. Dynamic personalities of proteins. Nature 450 (2007) 964-972
51. Henzler-Wildman K.A., Thai V., Lei M., Ott M., Wolf-Watz M., Fenn T., Pozharski E., Wilson M.A., Petsko G.A., Karplus M., et al. Intrinsic motions along an enzymatic reaction trajectory. Nature 450 (2007) 838-844
52. Hermans J., and Subramaniam S. The free energy of xenon binding to myoglobin from molecular dynamics simulation. Isr. J. Chem. 27 (1986) 225-227
53. Hermans J., and Wang L. Inclusion of the loss of translational and rotational freedom in theoretical estimates of free energies of binding. Application to a complex of benzene and mutant T4 lysozyme. J. Am. Chem. Soc. 119 (1997) 2707-2714
54. Hilser V.J., and Thompson E.B. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8311-8315
55. Huang N., and Jacobson M.P. Physics-based methods for studying protein-ligand interactions. Curr. Opin. Drug Discov. Dev. 10 (2007) 325-331
56. Huang N., Kalyanaraman C., Bernacki K., and Jacobson M.P. Molecular mechanics methods for predicting protein-ligand binding. Phys. Chem. Chem. Phys. 8 (2006) 5166-5177
57. Huey R., Morris G.M., Olson A.J., and Goodsell D.S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28 (2007) 1145-1152
58. Huo S., Wang J., Cieplak P., Kollman P.A., and Kuntz I.D. Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. J. Med. Chem. 45 (2002) 1412-1419
59. Jayachandran G., Shirts M.R., Park S., and Pande V.S. Parallelized-over-parts computation of absolute binding free energy with docking and molecular dynamics. J. Chem. Phys. 125 (2006) 084901
60. Jiao D., Golubkov P.A., Darden T.A., and Ren P. Calculation of protein-ligand binding free energy using a polarizable potential. Proc. Nat. Acad. Sci U.S.A. 105 (2008) 6290-6295
61. Jorgensen W.L. The many roles of computation in drug discovery. Science 303 (2004) 1813-1818
62. Kangas E., and Tidor B. Electrostatic complementarity at ligand binding sites: application to chorismate mutase. J. Phys. Chem. B 105 (2001) 880-888
63. Kim K.H. Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers?. J. Comput. Aided Mol. Des. 21 (2007) 421-435
64. Kim K.H. Outliers in SAR and QSAR: Is unusual binding mode a possible source of outliers?. J. Comput. Aided Mol. Des. 21 (2007) 63-86
65. Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., Lee M., Lee T., Duan Y., Wang W., et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33 (2000) 889-897
66. Kuhn B., and Kollman P.A. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J. Med. Chem. 43 (2000) 3786-3791
67. Kuntz I.D., Blaney J.M., Oatley S.J., Langridge R., and Ferrin T.E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161 (1982) 269-288
68. Laederach A., and Reilly P.J. Specific empirical free energy function for automated docking of carbohydrates to proteins. J. Comput. Chem. 24 (2003) 1748-1757
69. LaLonde J.M., Bernlohr D.A., and Banaszak L.J. X-ray crystallographic structures of adipocyte lipid-binding protein complexed with palmitate and hexadecanesulfonic acid. Properties of cavity binding sites. Biochemistry 33 (1994) 4885-4895
70. Lazaridis T., Matsunov A., and Gandolfo F. Contributions to the binding free energy of ligands to avidin and streptavidin. Proteins 47 (2002) 194-208
71. Leach A.R. Ligand docking to proteins with discrete side-chain flexibility. J. Mol. Biol. 235 (1994) 345-356
72. Lee M.S., and Olson M.A. Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. Biophys. J. 90 (2006) 864-877
73. Lee H., Reyes V.M., and Kraut J. Crystal structures of Escherichia coli dihydrofolate reductase complexed with 5-formyltetrahydrofolate (folinic acid) in two space groups: evidence for enolization of pteridine O4. Biochemistry 35 (1996) 7012-7020
74. Liverton N.J., Holloway M.K., McCauley J.A., Rudd M.T., Butcher J.W., Carroll S.S., DiMuzio J., Fandozzi C., Gilbert K.F., Mao S.-S., et al. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 130 (2008) 4607-4609
75. Lu Y., Wang C.-Y., and Wang S. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes. J. Am. Chem. Soc. 128 (2006) 11830-11839
76. Ma B., Shatsky M., Wolfson H.J., and Nussinov R. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci. 11 (2002) 184-197
77. Mardis K.L., Luo R., and Gilson M.K. Interpreting trends in the binding of cyclic ureas to HIV-1 protease. J. Mol. Biol. 309 (2001) 507-517
78. Meiler J., and Baker D.A. ROSETTALIGAND: protein-small molecule docking with full side-chain flexibility. Proteins 65 (2006) 538-548
79. Mewshaw R.E., Edsall Jr. R.J., Yang C., Manas E.S., Xu Z.B., Henderson R.A., Keith Jr. J.C., and Harris H.A. ERbeta ligands. 3. Exploiting two binding orientations of 2-phenylnapthalene scaffold to achieve ERbeta selectivity. J. Med. Chem. 48 (2005) 3953-3979
80. Miller D.W., and Dill K.A. Ligand binding to proteins: the binding landscape model. Protein Sci. 6 (1997) 2166-2179
81. Min W., English B.P., Luo G., Cherayil B.J., Kou S.C., and Xie X.S. Fluctuating enzymes: lessons from single-molecule studies. Acc. Chem. Res. 38 (2005) 923-931
82. Min W., Luo G., Cherayil B.J., Kou S.C., and Xie X.S. Observation of a power-law memory kernel for fluctuations within a single protein molecule. Phys. Rev. Lett. 94 (2005) 198302
83. Mobley D.L., Chodera J.D., and Dill K.A. On the use of orientational restraints and symmetry corrections in alchemical free energy calculations. J. Chem. Phys. 125 (2006) 084902
84. Mobley D.L., Chodera J.D., and Dill K.A. Confine-and-release method: obtaining correct binding free energies in the presence of protein conformational change. J. Chem. Theory Comput. 3 (2007) 1231-1235
85. Mobley D.L., Graves A.P., Chodera J.D., McReynolds A.C., Shoichet B.K., and Dill K.A. Predicting absolute ligand binding free energies to a simple model site. J. Mol. Biol. 371 (2007) 1118-1134
86. Mobley D.L., Dill K.A., and Chodera J.D. Treating entropy and conformational changes in implicit solvent simulations of small molecules. J. Phys. Chem. B 112 (2008) 938-946
87. Montfort W.R., Perry K.M., Fauman E.B., Finer-Moore J.S., Maley G.F., Hardy L., Maley F., and Stroud R.M. Structure, multiple site binding, and segmental accomodation in thymidylate synthase on binding dUMP and an anti-folate. Biochemistry 29 (1990) 6964-6977
88. Morton A., and Matthews B.W. Specificity of ligand binding in a buried nonpolar cavity of {T4} lysozyme: linkage of dynamics and structural plasticity. Biochemistry 34 (1995) 8576-8588
89. Murthy K.H.M., Winborne E.L., Minnich M.D., Culp J.S., and Debouck C. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. J. Biol. Chem. 267 (1992) 22770-22778
90. Najmanovich R., Kuttner J., Sobolev V., and Edelman M. Side-chain flexibility in proteins upon ligand binding. Proteins 39 (2000) 261-268
91. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
92. Olano L.R., and Rick S.W. Hydration free energies and entropies for water in protein interiors. J. Am. Chem. Soc. 126 (2004) 7991-8000
93. Oostenbrink C., and van Gunsteren W.F. Free energies of binding of polychlorinated biphenyls to the estrogen receptor from a single simulation. Proteins 54 (2004) 237-246
94. Orville A.M., Elango N., Lipscomb J.D., and Ohlendorf D.H. Structures of competitive inhibitor complexes of protocatechuate 3,4-dioxygenase: multiple exogenous ligand binding orientations within the active site. Biochemistry 36 (1997) 10039-10051
95. Pan C., Mezei M., Mujtaba S., Muller M., Zeng L., Li J., Wang Z., and Zhou M.M. Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor. J. Med. Chem. 50 (2007) 2285-2288
96. Paulsen M.D., and Ornstein R.L. Predicting the product specificity and coupling of cytochrome P450cam. J. Comput. Aided Mol. Des. 6 (1992) 449-460
97. Pearlman D.A. Evaluating the molecular mechanics poisson-boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. J. Med. Chem. 48 (2005) 7796-7807
98. Pearlman D.A., and Charifson P.S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J. Med. Chem. 44 (2001) 3417-3423
99. Pei Z., Li X., Longenecker K., Geldern T.W., Wiedeman P.E., Lubben T.H., Zinker B.A., Stewart K., Ballaron S.J., Stashko M.A., Mika A.K., Beno D.W., et al. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. J. Med. Chem. 49 (2006) 3520-3535
100. Perola E., and Charifson P.S. Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. J. Med. Chem. 47 (2004) 2499-2510
101. Pospisil P., Ballmer P., Scapozza L., and Folkers G. Tautomerism in computer-aided drug design. Journal of Receptors and Signal Transduction 23 (2003) 361-371
102. Raag R., and Poulos T.L. Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor, and adamantane: factors controlling P-450 substrate hydroxylation. Biochemistry 30 (1991) 2674-2684
103. Radivojac P., Iakoucheva L.M., Oldfield C.J., Obradovic Z., Uversky V.N., and Dunker A.K. Intrinsic disorder and functional proteomics. Biophys. J. 92 (2007) 1439-1456
104. Reddy M.R., and Erion M.D. Calculation of relative binding free energy differences for fructose 1,6-bisphosphatase inhibitors using the thermodynamic cycle perturbation approach. J. Am. Chem. Soc. 123 (2001) 6246-6252
105. Reich S.H., Melnick II M., Davies J.F., Appelt K., Lewis K.K., Fuhry M.A., Pino M., Trippe A.J., Nguyen D., Dawson H., et al. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3298-3303
106. Rizzo R.C., and Jorgensen W.L. OPLS all-atom model for amines: resolution of the amine hydration problem. J. Am. Chem. Soc. 121 (1999) 4827-4836
107. Rizzo R.C., Toba S., and Kuntz I.D. A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. J. Med. Chem. 47 (2004) 3065-3074
108. Roux B., Nina M., Poms R., and Smith J.C. Thermodynamic stability of water molecules in the bacteriorhodopsin proton channel: a molecular dynamics free energy perturbation study. Biophys. J. 71 (1996) 670-681
109. Ruvinsky A.M., and Kozintsev A.V. New and fast statistical-thermodynamic method for computation of protein-ligand binding entropy substantially improves docking accuracy. J. Comput. Chem. 26 (2005) 1089-1095
110. Schames J.R., Henchman R.H., Siegel J.S., Sotriffer C.A., Ni H., and McCammon J.A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 47 (2004) 1879-1881
111. Schwarzl S.M., Tschopp T.B., Smith J.C., and Fischer S. Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal-gas entropy correction?. J. Comput. Chem. 23 (2002) 1143-1149
112. Sharp K.A. Important considerations impacting molecular docking. In: Shoichet B.K., and Alvarez J. (Eds). Virtual Screening in Drug Discovery (2005), CRC Press, Boca Raton, FL
113. Sherman W., Day T., Jacobson M.P., Friesner R.A., and Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
114. Shirts M.R., Mobley D.L., and Brown S.P. Free energy calculations in structure-based drug design. In: Merz K.M., Ringe D., and Reynolds C.H. (Eds). Structure Based Drug Discovery (2009), Cambridge University Press, Cambridge
115. Shirts M.R., Mobley D.L., and Chodera J.D. Alchemical free energy calculations: ready for prime time?. Ann. Rep. Comput. Chem. 3 (2007) 41-59
116. Shoichet B.K., Leach A.R., and Kuntz I.D. Ligand solvation in molecular docking. Proteins 34 (1999) 4-16
117. Shoichet B.K., McGovern S.L., Wei B., and Irwin J.J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6 (2002) 439-446
118. Sousa S.F., Fernandes P.A., and Ramos M.J. Protein-ligand docking: current status and future challenges. Proteins 65 (2006) 15-26
119. Srinivasan J., Cheatham III T.E., Cieplak P., Kollman P.A., and Case D.A. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120 (1998) 9401-9409
120. Stauffer S.R., Stanton M.G., Gregro A.R., Steinbeiser M.A., Shaffer J.R., Nantermet P.G., Barrow J.C., Rittle K.E., Collusi D., Espeseth A.S., et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind [beta]-secretase in a N-terminal 10s-loop down conformation. Bioorg. Med. Chem. Lett. 17 (2007) 1788-1792
121. Steinbrecher T., Case D.A., and Labahn A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. J. Med. Chem. 49 (2006) 1837-1844
122. Steuber H., Czodrowski P., Sotriffer C.A., and Klebe G. Tracing changes in protonation: a prerequisite to binding to aldose reductase. J. Mol. Biol. 373 (2007) 1305-1320
123. Stoll V., Stewart K.D., Maring C.J., Muchmore S., Giranda V., Gu Y.G., Wang G., Chen Y., Sun M., Zhao C., et al. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry 42 (2003) 718-727
124. Stout T.J., Tondi D., Rinaldi M., Barlocco D., Pecorari P., Santi D.V., Kuntz I.D., Stroud R.M., Shoichet B.K., and Costi M.P. Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 38 (1999) 1607-1617
125. Stubbs M.T., Reyda S., Dullweber F., Moller M., Klebe G., Dorsch D., Mederski W.W.K.R., and Wurziger H. pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design. Chembiochem 3 (2002) 246-249
126. Sulsky R., Magnin D.R., Huang Y., Simpkins L., Taunk P., Patel M., Zhu Y., Stouch T.R., Bassolino-Klimas D., Parker R., et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg. Med. Chem. Lett. 17 (2007) 3511-3515
127. Tang C., Schweiters C.D., and Clore G.M. Open-to-closed transition in apo maltose-binding protein observed by paramagnetic NMR. Nature 449 (2007) 1078-1082
128. Taylor R.D., Jewsbury P.J., and Essex J.W. A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des. 16 (2002) 151-166
129. Teague S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2 (2003) 527-541
130. Tembe B.L., and McCammon J.A. Ligand-receptor interactions. Comput. Chem. 8 (1984) 281-283
131. Thomson J.A., and Perni R.B. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr. Opin. Drug Discov. Devel. 9 (2006) 606-617
132. Tirado-Rives J., and Jorgensen W.L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 49 (2006) 5880-5884
133. Uytterhoeven K., Sponer J., and Meervelt L.V. Two 1:1 binding modes for distamycin in the minor groove of d(GGCCAATTGG). Eur. J. Biochem. 269 (2002) 2868-2877
134. Vajpai N., Strauss A., Cowan-Jacob S.W., Manley P.W., Crzesiek S., and Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283 (2008) 18292-18302
135. Volkman B.F., Lipson D., Wemmer D.E., and Kern D. Two-state allosteric behavior in a single-domain signaling protein. Science 291 (2001) 2429-2433
136. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
137. Vorobjev Y.N., and Hermans J. ES/IS: estimation of conformational free energy by combining dynamics simulations with explicit solvent with an implicit solvent continuum model. Biophys. Chem. 78 (1999) 195-205
138. Wang J., Deng Y., and Roux B. Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. Biophys. J. 91 (2006) 2798-2814
139. Warren G.L., Andrews C.W., Capelli A.M., Clarke B., LaLonde J., Lambert M.H., Lindvall M., Nevins N., Semus S.F., Sender S., et al. A critial assessment of docking programs and scoring functions. J. Med. Chem. 49 (2006) 5912-5931
140. Warren, G., and Perola, E. (2008). Field of extremes: if you re-refine them, they will come down. Paper presented at CUP IX, March 16-19, 2008, Santa Fe, NM. Available online at http://www.eyesopen.com/about/events/cups-2008/pdfs-CUP/CUP9-Field-of-Extremes.pdf.
141. Warshel A., Sussman F., and King G. Free energy of charges in solvated proteins: microscopic calculations using a reversible charging process. Biochemistry 25 (1986) 8368-8372
142. Wei B.Q., Weaver L.H., Ferrari A.M., Matthews B.W., and Shoichet B.K. Testing a flexible-receptor docking algorithm in a model binding site. J. Mol. Biol. 337 (2004) 1161-1182
143. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
144. Wong C.F., and McCammon J.A. Dynamics and design of enzymes and inhibitors. J. Am. Chem. Soc. 108 (1986) 3830-3832
145. Wright P.E., and Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293 (1999) 321-331
146. Zhang L., and Hermans J. Hydrophilicity of cavities in proteins. Proteins Struct. Funct. Genet. 24 (1996) 433-438
147. Zhang X.J., Wozniak J.A., and Matthews B.W. Protein flexibility and adaptability seen in 25 crystal forms of T4 lysozyme. J. Mol. Biol. 250 (1995) 527-552
148. Zhou G., Ferrer M., Chopra R., Kapoor T.M., Strassmaier T., Weissenhorn W., Skehel J.J., Oprian D., Schreiber S.L., Harrison S.C., and Wiley D.C. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem. 8 (2000) 2219-2227